NICE "yes" for Allergan's Ozurdex after comparison with off-label Avastin
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal body for England and Wales, has recommended Allergan's dexamethasone intravitreal implant Ozurdex as an option for treating macular oedema following central and branch retinal vein occlusion (CRVO/BRVO). The yes came as NICE "commended" Allergan for its attempt to compare the relative clinical and cost effectiveness of Ozurdex and Roche's anticancer Avastin (bevacizumab).